Table 1 Demographics and cohort characteristics of the study population (n = 531).
Characteristics | n (%) | Characteristics | n (%) |
|---|---|---|---|
Age, year | Tobacco user | 99 (18.6) | |
Mean (SD) | 42.3 (10.5) | Comorbidities | |
Median (IQR) | 42 (35–50) | Type 2 Diabetes | 63 (11.8) |
Age category, (n, %) | Hypertension | 132 (24.9) | |
< 50 years | 390 (73.4) | Asthma | 45 (8.5) |
≥ 50 years | 141 (26.6) | NAb titers after 30 days of 2nd dosage | |
Sex (n, %) | Mean (SD) | 83.4 (21.4) | |
Male | 309(58.2) | Median (IQR) | 92 (78–97) |
Female | 222 (41.8) | NAb titer after 30 days of 2nd dosage (n, %) | |
BMI | < 70 | 90 (17.0) | |
Mean (SD) | 26.8 (3.4) | 70–95 | 213 (40.1) |
Median (IQR) | 25.6 (24.1–27.3) | ≥ 96 | 228 (42.9) |
BMI cut-off (n, %) | NAb titers after 180 days of 2nd dosage | ||
< 30 | 484 (91.1) | Mean (SD) | 54.9 (27.0) |
≥ 30 | 47 (8.9) | Median (IQR) | 58 (32–77) |
COVID-19 positive* | 129 (24.3) | NAb titer after 180 days of 2nd dosage (n, %) | |
Profession | < 70 | 318 (59.9) | |
Medical staff | 298 (56.1) | 70–95 | 186 (35.0) |
Non-medical staff | 233 (43.9) | ≥ 96 | 27 (5.1) |
